-
公开(公告)号：US11253587B2
公开(公告)日：2022-02-22
申请号：US17218148
申请日：2021-03-30
IPC分类号： A61K39/12 , A61K39/00 , C12N7/00 , C07K14/005 , A61K39/21 , A61K39/215
摘要： The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.
-
公开(公告)号：US20210353741A1
公开(公告)日：2021-11-18
申请号：US17218148
申请日：2021-03-30
IPC分类号： A61K39/215 , C12N7/00
摘要： The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.
-
公开(公告)号：US20120156240A1
公开(公告)日：2012-06-21
申请号：US13377365
申请日：2010-07-06
申请人： David E. Anderson , Andrei Ogrel
发明人： David E. Anderson , Andrei Ogrel
CPC分类号： A61K39/29 , A61K9/0019 , A61K9/127 , A61K9/1277 , A61K39/12 , A61K39/292 , A61K2039/542 , A61K2039/545 , A61K2039/55555 , A61K2039/55561 , C12N2730/10134 , C12N2770/32434 , Y02A50/464
摘要： The present disclosure provides methods for preparing vesicles. In some embodiments, the methods involve providing a molten mixture of vesicle forming lipids and then adding the molten mixture to an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. In other embodiments, the methods involve providing a lyophilized lipid product and rehydrating the lyophilized lipid product with an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. The lyophilized lipid product is prepared by melting vesicle-forming lipids to produce a molten lipid mixture and then lyophilizing the molten lipid mixture. The present disclosure also provides antigen-containing vesicle formulations prepared using these methods. The present disclosure also provides kits that include a lyophilized lipid product in a first container and an aqueous solution comprising an antigen in a second container.
摘要翻译： 本公开提供了制备囊泡的方法。 在一些实施方案中，所述方法包括提供形成囊泡的脂质的熔融混合物，然后将熔融混合物加入到包含抗原的水溶液中，使得形成含抗原的囊泡。 在其它实施方案中，所述方法包括提供冻干的脂质产物并用包含抗原的水溶液再次水合冻干的脂质产物，使得形成含抗原的囊泡。 冻干的脂质产物通过溶解形成囊泡的脂质以产生熔融脂质混合物，然后将熔融的脂质混合物冻干来制备。 本公开还提供了使用这些方法制备的含抗原的囊泡制剂。 本公开还提供了在第一容器中包含冻干的脂质产物和在第二容器中包含抗原的水溶液的试剂盒。
-
公开(公告)号：US20110020381A1
公开(公告)日：2011-01-27
申请号：US12875638
申请日：2010-09-03
申请人： Andrei OGREL
发明人： Andrei OGREL
IPC分类号： A61K39/145 , C07K7/08 , A61P31/16
CPC分类号： C07K14/005 , A61K39/12 , A61K39/145 , A61K2039/55505 , A61K2039/55566 , C12N2760/16122 , C12N2760/16134
摘要： Peptide-based anti-influenza formulations against influenza are disclosed. The peptides are derived from influenza-based epitopes. The formulations are based on peptide mixtures which may be formulated so that variability is present at particular residues. The formulations can be used to prepare vaccines for preventing influenza, particularly avian influenza.
摘要翻译： 公开了针对流感的基于肽的抗流感配制剂。 肽源自流感基因表位。 制剂基于可以配制成使得在特定残基处存在变异性的肽混合物。 该制剂可用于制备用于预防流行性感冒，特别是禽流感的疫苗。
-
公开(公告)号：US20230149537A1
公开(公告)日：2023-05-18
申请号：US17995546
申请日：2021-04-06
发明人： Fabian GUSOVSKY , Lynn HAWKINS , Sally ISHIZAKA , David Evander ANDERSON , Anne-Catherine FLUCKIGER
IPC分类号： A61K39/215 , A61P31/14
CPC分类号： A61K39/215 , A61P31/14 , A61K2039/5258
摘要： Provided herein are vaccines including coronavirus antigens and E6020, as well as methods of mitigation of coronavirus infection by administering those vaccines.
-
公开(公告)号：US11248026B2
公开(公告)日：2022-02-15
申请号：US15683355
申请日：2017-08-22
IPC分类号： A61K39/12 , A61P31/22 , C07K14/005 , A61K39/245 , A61K39/00
摘要： The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
公开(公告)号：US09907746B2
公开(公告)日：2018-03-06
申请号：US13377371
申请日：2010-07-06
CPC分类号： A61K9/0019 , A61K9/127 , A61K9/1277 , A61K39/12 , A61K2039/5252 , A61K2039/5254 , A61K2039/55555 , C12N2770/24234
摘要： The present disclosure provides methods for preparing vesicles. In general, these methods include steps of providing a lyophilized lipid product and rehydrating the lyophilized lipid product with an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. The lyophilized lipid product is prepared by dissolving vesicle-forming lipids in a polar-protic water-miscible organic solvent to produce a lipid solution and then lyophilizing the lipid solution. The present disclosure also provides antigen-containing vesicle formulations prepared using these methods. The present disclosure also provides kits that include a lyophilized lipid product in a first container and an aqueous solution comprising an antigen in a second container.
-
公开(公告)号：US09849173B2
公开(公告)日：2017-12-26
申请号：US13377365
申请日：2010-07-06
申请人： David E. Anderson , Andrei Ogrel
发明人： David E. Anderson , Andrei Ogrel
CPC分类号： A61K39/29 , A61K9/0019 , A61K9/127 , A61K9/1277 , A61K39/12 , A61K39/292 , A61K2039/542 , A61K2039/545 , A61K2039/55555 , A61K2039/55561 , C12N2730/10134 , C12N2770/32434 , Y02A50/464
摘要： The present disclosure provides methods for preparing vesicles. In some embodiments, the methods involve providing a molten mixture of vesicle forming lipids and then adding the molten mixture to an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. In other embodiments, the methods involve providing a lyophilized lipid product and rehydrating the lyophilized lipid product with an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. The lyophilized lipid product is prepared by melting vesicle-forming lipids to produce a molten lipid mixture and then lyophilizing the molten lipid mixture. The present disclosure also provides antigen-containing vesicle formulations prepared using these methods. The present disclosure also provides kits that include a lyophilized lipid product in a first container and an aqueous solution comprising an antigen in a second container.
-
公开(公告)号：US09777043B2
公开(公告)日：2017-10-03
申请号：US14357423
申请日：2012-11-09
IPC分类号： C07K14/00 , C07K14/005 , A61K39/245 , A61K39/00
CPC分类号： C07K14/005 , A61K39/245 , A61K2039/5258 , A61K2039/70 , C07K2319/00 , C07K2319/03 , C12N2710/16134 , C12N2740/13023 , C12N2760/20234
摘要： The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
公开(公告)号：US20130295165A1
公开(公告)日：2013-11-07
申请号：US13979322
申请日：2012-01-13
摘要： The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an attenuated or inactivated virus in combination with a non-ionic surfactant vesicle (NISV).
摘要翻译： 本公开提供了可用于治疗病毒感染的组合物和方法。 如本文所述，组合物和方法基于免疫原性组合物的开发，其包括与非离子表面活性剂囊泡（NISV）组合的减毒或灭活的病毒。
-
-
-
-
-
-
-
-
-
搜索结果
41 条记录 (耗时 0.029 秒)
